![]()
| As of Friday, November 13th: |
As of October 1st, the earnings growth rate was at -24.7%.Of the 463 S&P 500 companies who have reported Q3, 80% beat estimates, 6% were in-line, and 14% were below estimates. The blended earnings growth rate for the S&P 500 for Q3 2009 is currently at -13.8%. (Data provided by Thomson Reuters)
LATEST EARNINGS RESULTS
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Shift Into High-Quality Stocks Could Move Market Higher
- China: Low US Interest Rates Threaten Recovery
- Drug Study Questions Effectiveness of Merck's Drugs
- Buffett: I Haven't Bought AMEX Shares in Years
- Military Arms Race Dominates Dubai Air Show
- Disaster Film '2012' Drowns Rivals at Box Office
- Cities With the Most Home Price Reductions
- Cramer: 5 Earnings Reports to Watch Next Week
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
MOST SHARED
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. May Wind Up Green With Envy
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Dipping Into Green Investing
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- For Investors, The New Green Looks To Be White
- The Cost of Thanksgiving Dinner 2009
- Analysis: APEC Nations Back Face-Saving Climate Plan
- Japan's Largest Bank MUFG to Raise $11 Billion Equity
Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.
"Lilly had top-line strength across its portfolio, with each major therapeutic segment above our outlook," said Bear Stearns analyst John Boris. He noted the company's tax rate of
20.4 percent was less than his 22 percent forecast.
The Indianapolis-based drugmaker earned $854 million, or 78 cents per share. That compared with $132 million, or 12 cents per share, in the year-ago period, when Lilly took a big charge for a settlement with patients who claimed to have been harmed by its Zyprexa schizophrenia drug.
Top company officials remain upbeat about the future, despite signs of a softening economy.
"I'm not sure we can claim that our business is recession-proof, completely, but we stand by our guidance of double-digit earnings per share growth between now and 2011, compounded," Eli Lilly President & COO John Lechleiter told CNBC.
Lechleiter is scheduled to become the company's CEO on April 1.
Excluding special items, earnings rose 6 percent to 90 cents per share. Analysts on average had expected 89 cents per share, according to Reuters Estimates. The company took two charges, totaling 12 cents per share, related largely to restructuring and acquisitions.
Company global sales jumped 22 percent in the quarter to $5.19 billion, ahead of the Reuters Estimates forecast of $4.81 billion. Sales would have grown by 18 percent if not for the weak dollar, which boosts the value of overseas sales.
Sales of Zyprexa rose 10 percent to $1.27 billion, in a continuing rebound from earlier declines that had been sparked by concerns that the drug causes weight gains which raise diabetes risk.
Revenue from impotence treatment Cialis, which works far longer than Pfizer's Viagra and was recently approved in a new low-dose daily formulation, jumped 29 percent to $346 million.
Sales of Alimta, used to treat tumors caused by exposure to asbestos, soared 42 percent to $244 million, helped by its other approved use against lung cancer. Sales of Gemzar, an older lung cancer drug, rose 15 percent to $426 million.
Injectable diabetes drug Byetta, sold in partnership with Amylin Pharmaceuticals, gained ground from its wide use alongside oral treatments and its ability to help patients lose weight. Its global sales soared 34 percent to $184 million.
Humalog, a rapid-acting insulin used at mealtimes, was also a top performer during the quarter. Its sales jumped 18 percent to $414 million, helped by price increases and sizzling growth in overseas markets.
Lilly [LLY
Loading...
()
] said it is on track to meet its 2008 earnings target, excluding special items, of $3.85 to $4 per share -- driven by growing demand for Cymbalta, Cialis, Byetta, Alimta and Humalog. That would reflect profit growth of 9 to 13 percent from 2007 results.
CNBC.com contributed to this article.
- Disney Profit, Sales Top Forecasts; Shares Jump
Walt Disney shares rose in after-hours trading Thursday after the company reported earnings and revenue that beat analysts' expectations.
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
Nordstrom reported earnings that missed analysts expectations by a penny but beat on revenue, causing the company's shares to fall in after-hours trading.
- Wal-Mart Holiday Forecast Light, Profit Beats
Wal-Mart Stores posted a higher-than-expected quarterly profit, but forecast earnings during the key holiday quarter that could miss Wall Street estimates as its customers face rising unemployment.
- Disney Profit, Sales Top Forecasts; Shares Jump
- Kohl's Profit Beats Street, But Outlook Falls Short
Department store operator Kohl's Corp reported a larger-than-expected quarterly profit Thursday, but gave an outlook below Wall Street estimates for the period that includes the key holiday season.
- Kohl's Profit Beats Street, But Outlook Falls Short
- Vivendi Profit Up More Than 5%, Keeps 2009 Goals
- Cost Cuts Help BT to Raise Full-Year Guidance
- Applied Materials Profit, Sales Top Wall Street Forecasts
- Macy's Loss Beats Estimates, But Shares Fall on Outlook
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
- Tyco International Profit Falls Less Than Expected
- EA Profit Beats Street, Announces Job Cuts
- Priceline Crushes Profit Forecasts; Shares Jump
- Berkshire Hathaway Says Net Income Tripled
- Sun Micro Sales Fall as Oracle Deal Remains Delayed
- AIG in the Black Again, Operating Profit Tops View
- Starbucks Profit Beats Forecasts; Shares Rise
- Fannie Mae Seeks $15 Billion in Aid After Posting Loss
- Nvidia Profit, Sales Top Wall Street's Forecast
- CBS Beats Expectations on Improved Ad Market








